Search 

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET

Jianmin Group (600976.SSE) is an integrated pharmaceutical company with a major focus on pediatric product development, manufacture, and marketing. Founded in 1953, headquartered in Wuhan, the largest city in Central China, its history can be traced back to 17th century. Jianmin has been a famous pharma brand in China among children and their parents for generations. Its rich pediatric portfolio ranges from nutrition, hematology, respiratory, digestive, CNS, to infections and common cold as well.

Kymeris Therapeutics (Canada) has exlusive license to a ground-breaking cell-based immunotherapeutic product for clinical development in cancer. This multivalent anti-cancer platform integrates multiple mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses encoded biodrugs in the cancer - but not systemically.

*  We are seeking partners with small molecule or antibody (or any encodable peptide or protein) that would have an enabling platform compared to intravenous or intratumoral formulations.

*  We are also seeking strategic investors in the platform that has extremely high potential in future products, adaptable against almost any solid cancer.

------------------------------------------------------------------

The platform can enable, or enhance, additional small molecule, antibody, peptide or cytokine agents.  It is a preclinical late-stage firm that has discovered and developed a First-in-Class immunotherapeutic platform based on non-pathogenic eukaryotes (nucleated cells, non-viral, non-bacterial). Our platform is original with the first scientific paper just published in November 2020 by the Journal of Immunotherapy of Cancer (BMJ), and our first scientific presentation at the 2020 Annual Meeting of the SITC where we presented recent report on a derivative that secreted human IL-15 within tumor, but devoid of serum detection of the cytokine.

The platform would be a paradigm shift from "reductive" (targeted, mono-mechanism) approaches, and can be encoded with additional molecular therapies to more comprehensively face the complex of solid cancer defenses. Encoding any biological agent (small molecule, antibody, antigen, cytokine...), could enable that agent for a wider scope of applications,  enhanced effect and much safer profile.  In addition, the platform shows abscopal effect, an ability to reach tumors after administration from a distance (subcutaneous or mucosal).

The platform has shown the following characteristics:

1. Tumor-tropism / Cancer-agnostic. Homing to tumor occurred in the absence of a cancer antigen marker (TAA or TSA), and may even work in tumors that are not easily "targetable", such as "cold", lacking cancer markers, heterogeneic or mutating tumors. One oncologist remarked, "This turns "cold" tumors "hot" ".The agents have had effect at distance from tumor site when administered subcutaneously or mucosally. 

 2. Tumor-infiltration + TME counteraction. The agents bear a specialized "universal key" to gain entry into mammalian cell in an active process; no specific  receptor needed. In addition, the agents are able to reprogram tolerogenic cells into a state of immune competence i.e. to overcome cancer-induced immune suppression within the tumor.

3. Intra-cancer delivery of any payload/s. Obligate intracellular microbes, the agents infect cancer cells and replicate, expressing encoded biodrugs. The replication continues as long as there is cancer tissue to infect and/or the TME has not been disabled.  Any agents outside of the TME were naturally cleared in under 10 days.

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates in other international markets. Along with a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. Europe and Japan, Luye Pharma has reached high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems, as well as actively making strategic developments in the fields of biological antibodies, cell therapies and gene therapies, among others.

Luye Pharma is developing a global supply chain of 8 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as in fast growing emerging markets.